CN114369022B - 马齿苋中一种有机酸类化合物及其提取分离方法 - Google Patents
马齿苋中一种有机酸类化合物及其提取分离方法 Download PDFInfo
- Publication number
- CN114369022B CN114369022B CN202110642216.8A CN202110642216A CN114369022B CN 114369022 B CN114369022 B CN 114369022B CN 202110642216 A CN202110642216 A CN 202110642216A CN 114369022 B CN114369022 B CN 114369022B
- Authority
- CN
- China
- Prior art keywords
- methanol
- elution
- water
- organic acid
- extraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 Organic acid compound Chemical class 0.000 title claims abstract description 57
- 238000000926 separation method Methods 0.000 title claims abstract description 28
- 238000000605 extraction Methods 0.000 title claims abstract description 27
- 241000219304 Portulacaceae Species 0.000 title claims abstract description 24
- 235000001855 Portulaca oleracea Nutrition 0.000 title claims abstract description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000002253 acid Substances 0.000 claims abstract description 20
- 150000001875 compounds Chemical class 0.000 claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 16
- 238000010898 silica gel chromatography Methods 0.000 claims abstract description 10
- 238000004440 column chromatography Methods 0.000 claims abstract description 7
- 238000004128 high performance liquid chromatography Methods 0.000 claims abstract description 7
- 239000011347 resin Substances 0.000 claims abstract description 7
- 229920005989 resin Polymers 0.000 claims abstract description 7
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 claims abstract description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 87
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 39
- 238000010828 elution Methods 0.000 claims description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- 238000010829 isocratic elution Methods 0.000 claims description 8
- 239000000741 silica gel Substances 0.000 claims description 8
- 229910002027 silica gel Inorganic materials 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 239000002024 ethyl acetate extract Substances 0.000 claims description 6
- 238000001704 evaporation Methods 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 6
- 239000000047 product Substances 0.000 claims description 6
- 238000004809 thin layer chromatography Methods 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- 238000013375 chromatographic separation Methods 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000011068 loading method Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 239000003086 colorant Substances 0.000 claims description 2
- 239000000706 filtrate Substances 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- HQVFCQRVQFYGRJ-UHFFFAOYSA-N formic acid;hydrate Chemical compound O.OC=O HQVFCQRVQFYGRJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000000401 methanolic extract Substances 0.000 claims description 2
- 235000008216 herbs Nutrition 0.000 claims 1
- 102000003914 Cholinesterases Human genes 0.000 abstract description 6
- 108090000322 Cholinesterases Proteins 0.000 abstract description 6
- 229940048961 cholinesterase Drugs 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 6
- 238000002360 preparation method Methods 0.000 abstract description 5
- 238000000746 purification Methods 0.000 abstract description 5
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 abstract description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 abstract description 4
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 230000003334 potential effect Effects 0.000 abstract 1
- 238000010183 spectrum analysis Methods 0.000 abstract 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 229910001175 oxide dispersion-strengthened alloy Inorganic materials 0.000 description 8
- 238000001228 spectrum Methods 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 210000002540 macrophage Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 102100033639 Acetylcholinesterase Human genes 0.000 description 6
- 108010022752 Acetylcholinesterase Proteins 0.000 description 6
- 229940022698 acetylcholinesterase Drugs 0.000 description 6
- 238000001052 heteronuclear multiple bond coherence spectrum Methods 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 4
- 108010002352 Interleukin-1 Proteins 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 3
- 229920005654 Sephadex Polymers 0.000 description 3
- 239000012507 Sephadex™ Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000000544 cholinesterase inhibitor Substances 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 3
- 235000019799 monosodium phosphate Nutrition 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 229960001697 physostigmine Drugs 0.000 description 3
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 241000219295 Portulaca Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000005100 correlation spectroscopy Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- SZMVXHRECFRCKQ-UHFFFAOYSA-M 2-ethanethioyloxyethyl(trimethyl)azanium;iodide Chemical compound [I-].CC(=S)OCC[N+](C)(C)C SZMVXHRECFRCKQ-UHFFFAOYSA-M 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- FZNMBBPKZSTVOR-UHFFFAOYSA-N 4-hydroxy-5-methylfuran-3-carboxylic acid Chemical compound CC=1OC=C(C(O)=O)C=1O FZNMBBPKZSTVOR-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- PCSKKIUURRTAEM-UHFFFAOYSA-N 5-hydroxymethyl-2-furoic acid Chemical compound OCC1=CC=C(C(O)=O)O1 PCSKKIUURRTAEM-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- FRPHFZCDPYBUAU-UHFFFAOYSA-N Bromocresolgreen Chemical compound CC1=C(Br)C(O)=C(Br)C=C1C1(C=2C(=C(Br)C(O)=C(Br)C=2)C)C2=CC=CC=C2S(=O)(=O)O1 FRPHFZCDPYBUAU-UHFFFAOYSA-N 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010054787 Haemorrhoidal haemorrhage Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- WYGMGKPKILJUQX-UHFFFAOYSA-N [N+](=O)([O-])C1=C(C(=O)O)C=C(C=C1)SSC=1C=CC(=C(C(=O)O)C1)[N+](=O)[O-].[P] Chemical compound [N+](=O)([O-])C1=C(C(=O)O)C=C(C=C1)SSC=1C=CC(=C(C(=O)O)C1)[N+](=O)[O-].[P] WYGMGKPKILJUQX-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000006481 glucose medium Substances 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 1
- 238000000990 heteronuclear single quantum coherence spectrum Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- YQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 description 1
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 description 1
- 231100000747 viability assay Toxicity 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/03—Monocarboxylic acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
- C07C51/47—Separation; Purification; Stabilisation; Use of additives by solid-liquid treatment; by chemisorption
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Botany (AREA)
- Psychiatry (AREA)
- Compounds Of Unknown Constitution (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及中药提取、分离领域,尤其涉及从马齿苋中提取、分离和鉴别出的有机酸类化合物及其提取分离方法。所述的有机酸类化合物,分子式为C15H24O2,命名为(7E,9E,12E)‑pentadecyl‑7,9,12‑trienoic acid。还提供上述有机酸类化合物的提取分离方法,依次采用水煎煮提取、硅胶柱层析、大孔树脂柱层析、ODS中压柱、硅胶柱层析、Sephadex LH‑20纯化及HPLC分离制备。其结构采用1H‑NMR、13C‑NMR及二维核磁波谱解析的方法确定为一种新有机酸类化合物。该化合物具有潜在的抗炎和抗胆碱酯酶等活性,并提供制备方法,为开发新药和开发新成分提供先导物和理论依据。
Description
技术领域
本发明涉及中药提取、分离领域,尤其涉及从马齿苋药材中提取、分离和鉴别出的有机酸类化合物及其提取分离方法。
背景技术
马齿苋(Portulaca oleracea L.),又名长命菜、马苋菜,为马齿苋科马齿苋属植物。马齿苋耐旱耐涝,且耐光耐阴,分布广泛、资源丰富,作为药食两用的野生植物备受关注。2020版《中华人民共和国药典》中收载马齿苋的干燥地上部分入药,具有清热解毒、凉血止血、止痢等功效,用于热毒血痢、痈肿疔疮、湿疹、丹毒、蛇虫咬伤、便血、痔血、崩漏下血等。
马齿苋现代药理学研究表明,其具有抗炎止痛、抗菌、抗病毒、降血压、降血脂、抗氧化、抗癌、松弛骨骼肌和平滑肌、调节免疫功能等作用。研究表明马齿苋众多化学成分为其多样的药理作用提供了物质基础,马齿苋主要化学成分包括黄酮类、香豆素类、萜类、甾类、有机酸类、挥发油、生物碱类、氨基酸类、各种色素类和矿物质类等。其中有机酸类是马齿苋中一类主要的化学成分,目前已报道的有机酸类成分有4-羟基-5-甲基呋喃-3-羧酸、5-羟甲基糠酸、L-焦谷氨酸、水杨酸、香草酸、对羟基苯甲酸、硬脂酸、棕榈酸、油酸、亚油酸和亚麻酸等。
目前从马齿苋中分离出的化学成分大多数是已知的,且结构新颖性较低,因此,对马齿苋中新化合物的开发和分离是亟待需要的。
发明内容
针对上述问题,本发明提供从马齿苋中提取的一种有机酸类化合物,经研究发现本发明的新化合物具有抗炎和抗胆碱酯酶的作用,同时提供一种针对本发明新化合物的简便、快速、环保、纯度高的提取分离方法。
为了实现上述目的,本发明提供了如下技术方案。
本发明提供了一种从马齿苋药材中分离出的有机酸类化合物,其特征在于,所述化合物的分子式为:C15H24O2,并且根据结构命名为(7E,9E,12E)-pentadecyl-7,9,12-trienoic acid,其化学结构式如下:
本发明还提供了一种如权利要求1所述的有机酸类化合物的提取分离方法,其特征在于,提取分离方法的具体步骤为:
步骤1:取马齿苋干燥药材,采用水提取两次,水提液过滤,合并滤液直接加热浓缩,放凉至室温,得药液备用;
步骤2:将步骤1中的药液蒸干后上硅胶柱,用乙酸乙酯洗脱,减压回收乙酸乙酯至浸膏,得到乙酸乙酯提取物;
步骤3:将步骤2中的乙酸乙酯提取物经大孔树脂柱分离,采用乙醇∶水梯度洗脱,50%乙醇部分蒸干后上经预处理的ODS柱,用甲醇∶水洗脱,回收70%甲醇部分至浸膏,得到70%甲醇提取物;
步骤4:将步骤3中所得物再经硅胶柱进行层析分离,用乙酸乙酯进行洗脱,得到若干洗脱部位,经薄层色谱进行检测、显色,将各显色的洗脱部位分别减压浓缩至干,得到浓缩物备用;
步骤5:将步骤4中所得物再经预处理的葡聚糖凝胶柱层析分离,用甲醇洗脱,得到若干洗脱部位,经薄层色谱进行检测,显色,合并显色的洗脱部位,将合并后的洗脱部位经减压浓缩至干,备用;
步骤6:将步骤5中的浓缩物通过HPLC分离制备,以甲醇∶0.1%甲酸水为流动相进行等度洗脱,最终得到本发明所述的新化合物。
进一步地,所述步骤1中水煎煮提取两次,每次煎煮2小时,水用量为药材的10倍。
进一步地,所述步骤3中ODS和步骤5中的Sephadex LH-20凝胶的预处理过程为甲醇浸泡过24小时,上柱,以初始流动相平衡。
进一步地,所述步骤2中所用流动相洗脱程序为等度洗脱。
进一步地,所述步骤3中大孔树脂柱分离所用体积比为0∶100、30∶70、50∶50、70∶30、100∶0的乙醇∶水梯度洗脱,步骤4中的硅胶层析分离用乙酸乙酯进行等度洗脱。
进一步次,所述步骤3中所用甲醇∶水梯度洗脱中甲醇和水的体积比为50∶50、60∶40、70∶30、80∶20、90∶10、100∶0。
进一步地,所用步骤5中所用甲醇等度洗脱。
进一步地,所述步骤6中所用甲醇∶0.1%甲酸等度洗脱中甲醇和水的体积比为85∶15。
本发明还提供一种如权利要求1所述的有机酸类化合物的用途,其特征在于,所述用途可用于制备抗炎和抗胆碱酯酶的药物或保健品。
与现有技术相比本发明的有益效果。
本发明中所述马齿苋有机酸类化合物的分离和药理活性研究未被现有论文期刊所报道。本发明提供来源于马齿苋的有机酸类化合物及一种针对本发明化合物的提取分离方法,依次采用水煎煮提取、硅胶柱层析、大孔树脂柱层析、硅胶柱层析、ODS中压柱纯化、硅胶柱层析、Sephadex LH-20及HPLC进行分离纯化与制备,成功提取分离出一种的有机酸类化合物。该方法操作步骤仅为七步,操作方法简便及快速,提取分离过程主要采用水煎煮提取及乙酸乙酯洗脱,工艺方法环保,且经该方法分离得到的化合物纯度较高且大于90%。此外经研究表明该化合物具有抗炎和抗胆碱酯酶作用,因此本发明化合物及其盐和衍生物可以作为其他化合物合成先导物,以及新药开发和药理活性研究的原料,亦可用于制备抗炎和抗胆碱酯酶的药物。
附图说明
图1为本发明有机酸化合物(7E,9E,12E)-pentadecyl-7,9,12-trienoic acid的紫外光谱图。
图2为本发明有机酸化合物(7E,9E,12E)-pentadecyl-7,9,12-trienoic acid的红外光谱图。
图3为本发明有机酸化合物(7E,9E,12E)-pentadecyl-7,9,12-trienoic acid的高分辨质谱图。
图4为本发明有机酸化合物(7E,9E,12E)-pentadecyl-7,9,12-trienoic acid的1H-NMR光谱图。
图5为本发明有机酸化合物(7E,9E,12E)-pentadecyl-7,9,12-trienoic acid的13C-NMR光谱图。
图6为本发明有机酸化合物(7E,9E,12E)-pentadecyl-7,9,12-trienoic acid的DEPT135光谱图。
图7为本发明有机酸化合物(7E,9E,12E)-pentadecyl-7,9,12-trienoic acid的1H-1HCOSY光谱图。
图8为本发明有机酸化合物(7E,9E,12E)-pentadecyl-7,9,12-trienoic acid的HMBC光谱图。
图9为本发明有机酸化合物(7E,9E,12E)-pentadecyl-7,9,12-trienoic acid的HSQC光谱图。
具体实施方式
下面结合具体实施例对本发明做详细的说明。
实施例1。
本发明提供一种有机酸类化合物,分子式分别为C15H24O2,命名为(7E,9E,12E)-pentadecyl-7,9,12-trienoic acid,化学结构式分别为:
所述一种有机酸类化合物根据结构分别命名为(7E,9E,12E)-pentadecyl-7,9,12-trienoic acid,表1为该一种有机酸类化合物的核磁数据:1H-NMR与13C-NMR在DMSO-d 6中。
表1:本发明有机酸类化合物(7E,9E,12E)-pentadecyl-7,9,12-trienoic acid的核磁数据
本发明一种有机酸类化合物(7E,9E,12E)-pentadecyl-7,9,12-trienoic acid的结构鉴定及推导。
(7E,9E,12E)-pentadecyl-7,9,12-trienoic acid:黄色油状物,难溶于甲醇,易溶于氯仿。点样于硅胶薄层板后,喷溴甲酚绿试液斑点呈淡黄色。UV(MeOH)λmax:206nm。IR(KBr)v max:3420、1716cm-1。HR-ESI(+)TOF-MS给出m/z:313.1071[M-H]-的准分子离子峰,分子量为235.1705。结合1H-NMR、13C-NMR以及DEPT135光谱数据,推断该化合物分子式为具有6个不饱和度的C15H24O2。该有机酸的1H-NMR光谱中,在δ0.92(t,3H,J=7.50Hz)处产生信号证明存在甲基,并且有7个亚甲基信号在δ2.18(m,2H),1.47(br,2H),1.25(br,2H),1.30(br,2H),2.03(m,4H,重叠)和2.77(t,2H,J=6.30Hz);在δ5.35(m,1H,J=16.68Hz),5.30(m,1H,J=17.46Hz),5.34(m,1H,J=13.50Hz),5.31(m,1H,J=16.92Hz),5.33(m,1H,J=16.38Hz)和5.36(m,1H,J=16.38Hz)处产生6个烯氢信号;1个羟基的活泼氢在δ9.66(t,1H,J=1.62Hz)处产生信号。13C-NMR光谱和DEPT135光谱显示15个碳信号,包括一个甲基信号(δ14.09),七个亚甲基信号(δ33.65、24.47、28.49、28.96、26.59、25.09、20.02),六个烯烃次甲基信号(δ129.88、126.96、127.88、127.93、127.54、131.48)以及一个季碳信号(δ174.50)。1H-1H COSY光谱显示该化合物的H-2/H-3/H-4/H-5/H-6/H-7/H-8/H-9/H-10/H-11/H-12/H-13/H-14/H-15之间存在强烈的相关。同时,HMBC光谱也显示出H-2与C-1,3,4相关;H-3与C-1,2,4相关;H-4与C-2,3,5,6相关;H-5与C-3,4,6,7相关;H-6与C-4,5,7,8相关;H-7与C-5,6,8,9相关;H-8与C-6,9,10相关;H-9与C-7,11相关;H-10与C-8,9,11,12相关;H-11与C-9,10,12,13相关;H-12与C-10,11,13,14相关;H-13与C-11,12,14,15相关;H-14与C-12,13,15相关;H-15与C-13,14相关。由此我们可以根据1H-1H COSY光谱和HMBC光谱的相关性推断出有一个长碳链的存在。HMBC光谱中有一个明显的δH2.18与δC174.50的相关信号,此外,由于δH2.18与δC174.50的羧基碳相连,导致了亚甲基质子向低场移动,这使我们可以确定δH2.18和δC33.6直接相连并位于C-2位上。又因位于低场的δ2.03(m,4H,重叠)的氢信号显示该位上的氢与碳碳双键相连,并且δH2.03与δC127.88和126.96以及δH2.03与δC131.48在HMBC光谱中存在相关,这可以确定,位于6位上的碳与7位上的碳连接,14位的碳与13位上的碳相连。根据六个烯烃氢的偶合常数,可以证明化合物中的双键全部为反式双键。根据发生了低场化学位移的亚甲基质子δ2.77(t,2H,J=6.12Hz)以及HMBC光谱中的δH2.77与δC127.88、127.93、127.54和131.48的强相关信号,可推断出了两个烯键之间存在的一个亚甲基(δ2.77),这样我们便可确定δH2.77/δC25.1在C-11处。HMBC光谱中存在的δH0.92与δC131.48的明显相关信号,并且δH0.92处的峰分裂为三重峰,这表明该质子与亚甲基相连,因此得到13位上的碳原子连接有一个乙基。根据以上信息,可确定此有机酸类化合物为上述结构。
本发明还提供上述有机酸化合物的提取分离方法,具体步骤为:
步骤1:称取马齿苋干燥药材150kg,采用水回流提取,水用量(v/v)为药材的10倍,回流提取两次,每次2h,90℃~100℃加热浓缩至150L,放凉至室温,得药液备用;
步骤2:将步骤1中所得药液蒸干后经硅胶柱层析分离,用乙酸乙酯(115L)等度洗脱,其中硅胶为100目~200目,40℃以下减压回收乙酸乙酯至浸膏,得到乙酸乙酯提取物;
步骤3:将步骤2中乙酸乙酯提取物经大孔树脂柱分离,采用乙醇∶水(0∶100、30∶70、50∶50、70∶30、100∶0,v/v)梯度洗脱,50%(体积百分数)乙醇部分蒸干后上经预处理的ODS柱层析分离,其中填料粒度为20μm~40μm,依次用甲醇∶水(50∶50,60∶40,70∶30,80∶20,90∶10,100∶0,v/v)梯度洗脱(加压,使流速为1mL/min,温度为室温),合并70%甲醇洗脱部位并回收甲醇至浸膏,得到70%甲醇提取物;
步骤4:将步骤3中所得物再经硅胶柱层析分离,其中硅胶为200目~300目,用乙酸乙酯等度洗脱,得到18个部位(即梯度洗脱得18个瓶,每瓶200mL),经薄层色谱进行检测、显色,留下显色的第3部位,50℃以下减压浓缩至干,备用;
步骤5:将步骤4中所得的第3部位再经预处理的葡聚糖凝胶柱层析分离,用甲醇洗脱,得到26个洗脱部位(即共得到26个瓶,每瓶50mL),经薄层色谱进行检测,显色,将显色的10~13部位合并,50℃以下减压浓缩至干,备用;
步骤6:将步骤5中所得的显色部位经HPLC分离制备,以甲醇∶0.1%甲酸水(85∶15,v/v)作为流动相,检测波长为210nm和280nm,分离制备得到本发明有机酸类化合物,归一法测定纯度为98%。
所述ODS与葡聚糖凝胶的预处理过程为甲醇浸泡过24h,上柱,以初始流动相平衡。
实施例2本发明有机酸化合物的抗炎作用。
1 主要材料。
1.1 药品和试剂:实验所用有机酸化合物由上述方法制备,纯度为98%,精密称取,用DMSO稀释至下述各剂量组所需溶液。DMEM高糖培养基、胎牛血清(美国Hyclone公司);青霉素、链霉素(杭州四季青公司);LPS(美国Sigma公司);IL-1β和TNF-α的ELISA试剂盒(美国Cayman公司);细胞裂解液(碧云天生物技术有限公司)。
1.2 细胞株:RAW264.7巨噬细胞(美国ATCC细胞库)。
1.3 分组:分为LPS组和实验组,各一组。
2 实验方法。
2.1 细胞培养:DMEM高糖培养基,加入l0%的胎牛血清,l%抗菌素(100U/mL青霉素和100μg/mL链霉素),置于37.5%,CO2培养箱中培养。
2.2 MTT比色法测定细胞活力:上述三组分别取对数生长期RAW264.7巨噬细胞接种于96孔培养板中,细胞密度为1×104个/mL,每孔100μL,温度37℃,5%CO2条件下培养过夜后,实验组加入不同浓度的本发明有机酸化合物(7E,9E,12E)-pentadecyl-7,9,12-trienoic acid(1μM~100μM),孵育1h后向LPS组和实验组分别加入终浓度为1μg/mL的LPS,另设调零组(含DMSO溶媒的培养液),每组设3个复孔,考察加入药物后对细胞的影响。上述各组细胞培养24h后,在各孔细胞中加入20μL的浓度为5mg/mL的MTT,温度37℃,5%CO2条件下继续孵育4h后,终止培养,吸弃孔内液体,每孔加入100μL二甲基亚砜(DMSO),振荡10min,使细胞内结晶充分溶解,酶标仪570nm波长处测定各孔吸光值。
2.3 ELISA法测定炎症因子IL-1β和TNF-α:将对数生长期RAW264.7巨噬细胞接种于24孔培养板中,细胞密度为1×105个/mL,每孔1mL,温度37℃,5%CO2条件下培养过夜,实验组加入本发明的有机酸化合物(7E,9E,12E)-pentadecyl-7,9,12-trienoic acid(1μM~50μM),培育1h后,在每孔加入LPS(终浓度为1μg/mL),共孵育24h,每组处理重复3孔。ELISA法测定该马齿苋来源新有机酸化合物处理后的RAW264.7巨噬细胞分泌的IL-1β和TNF-α的含量。
3 实验结果。
实验结果表明本发明的有机酸化合物对LPS诱导的巨噬细胞RAW264.7的增殖无影响,安全无毒;并可有效抑制LPS诱导的巨噬细胞RAW264.7所产生过量炎症细胞因子IL-1β和TNF-α,且呈浓度依赖。
细胞相对存活率实验结果如表2所示。
表2:本发明对RAW264.7巨噬细胞相对存活率的影响
注:*P<0.05与LPS组比较(高浓度组有显著性差异)。
ELISA法测定炎症因子IL-1β和TNF-α结果如表3所示。
表3:本发明对LPS诱导的RAW264.7细胞分泌的IL-1β和TNF-α含量的影响
注:*P<0.05与对照组比较,均数±SD,n=3。
实施例3本发明有机酸类化合物的抗胆碱酯酶作用。
1 主要材料。
1.1药品和试剂:实验所用有机酸类化合物由上述方法制备,纯度为90%~99%,磷酸二氢钠、磷酸氢二钠(国药集团化学试剂有限公司),毒扁豆碱(瀚翔生物科技),磷5,5'-二硫代双(2-硝基苯甲酸)(Dithiobisnitrobenzoic acid,DTNB,上海金穗生物科技有限公司),乙酰胆碱酯酶(AChE)和碘化硫代乙酰胆碱(Acetylthiocholine iodide,ATCI,大连美仑生物技术有限公司)。
1.2分组:分为阴性对照组、阳性对照组和实验组,各一组。
2 实验方法。
2.1样品准备,分别精密称取样品和毒扁豆碱1mg,分别以甲醇为溶剂,配置成lmg/mL、0.5mg/mL、0.1mg/mL、0.05mg/mL、0.01mg/mL的五个梯度浓度。分别精密称取7.098g的磷酸二氢钠和5.999g的磷酸氢二钠,用蒸馏水定容至50mL,取3.40mL的磷酸二氢钠和46.6mL的磷酸氢二钠,配制成50mL的PBS(0.1M,pH=8.0);精密称取0.0594g的DTNB,加入10mL的PBS,配制成DTNB溶液(15mmol/L);精密称取0.01g的AChE,加入10mL的PBS,配制成AChE溶液(0.2U/mL);精密称取0.044gATCI,用蒸馏水定容至10mL,配制成ATCI溶液(15mmol/L)。
2.2改进的Ellman方法测定抗胆碱酯酶活性,在96孔酶标板中依次加入140μL的PBS(0.1M,pH=8.0),10μL的DTNB(15mmol/L),15μL的AChE(0.2U/mL),20μL样品溶液。阴性对照组实验用甲醇代替样品,阳性对照组实验用毒扁豆碱代替样品。37℃孵育10min后,加10μL的ATCI(15mmol/L)。20℃孵育10min后,用酶标仪在410nm下测定其吸光度值。
根据下式计算抑制率:抑制率(%)=(空白组-样品)/空白组×100%。
3 实验结果。
实验结果表明本发明生物碱化合物有抗胆碱酯酶作用。
实验结果如表4所示。
表4:本发明化合物对乙酰胆碱酯酶的抑制作用
综上所述,本发明提供一种有机酸化合物及其提取分离方法,依次采用水煎煮提取、硅胶柱层析、大孔树脂柱层析、ODS中压柱纯化、硅胶柱层析、Sephadex LH-20及HPLC进行分离纯化与制备,成功的分离得到该化合物。该方法简便、快速、环保,且经该方法分离得到的化合物纯度较高。由于所得化合物化学结构独特,从常用中药马齿苋中提取出来,其具有抗炎和抗胆碱酯酶作用,因此本发明的新有机酸化合物及其盐和衍生物可以作为天然产物开发中药新药,具有广阔的前景。
Claims (7)
1.一种从马齿笕药材中分离出的有机酸类化合物的提取分离方法,其特征在于,提取分离方法的具体步骤为:
步骤1:取马齿苋干燥药材,采用水提取两次,水提液过滤,合并滤液直接加热浓缩,放凉至室温,得药液备用;
步骤2:将步骤1中的药液蒸干后上硅胶柱,用乙酸乙酯洗脱,减压回收乙酸乙酯至浸膏,得到乙酸乙酯提取物;
步骤3:将步骤2中的乙酸乙酯提取物经大孔树脂柱分离,采用乙醇∶水梯度洗脱,乙醇∶水的体积比为0∶100、30∶70、50∶50、70∶30、100∶0,50%乙醇部分蒸干后上经预处理的ODS柱,用甲醇∶水梯度洗脱,甲醇和水的体积比为50∶50、60∶40、70∶30、80∶20、90∶10、100∶0,回收70%甲醇部分至浸膏,得到70%甲醇提取物;
步骤4:将步骤3中所得物再经硅胶柱进行层析分离,用乙酸乙酯进行洗脱,得到若干洗脱部位,经薄层色谱进行检测、显色,将各显色的洗脱部位分别减压浓缩至干,得到浓缩物备用;
步骤5:将步骤4中所得物再经预处理的葡聚糖凝胶Sephadex LH-20柱层析分离,用甲醇洗脱,得到若干洗脱部位,经薄层色谱进行检测,显色,合并显色的洗脱部位,将合并后的洗脱部位经减压浓缩至干,备用;
步骤6:将步骤5中的浓缩物通过HPLC分离制备,以甲醇∶0.1%甲酸水为流动相进行等度洗脱,最终得到所述的化合物;
所述化合物的分子式为:C15H24O2,并且根据结构命名为(7E,9E,12E)-pentadecyl-7,9,12-trienoic acid,其化学结构式如下:
2.如权利要求1所述提取分离方法,其特征在于,所述步骤1中采用水煎煮提取两次,每次煎煮2小时,水用量为药材的10倍。
3.如权利要求1所述的提取分离方法,其特征在于,所述步骤3中ODS和步骤5中的Sephadex LH-20凝胶的预处理过程为甲醇浸泡过24小时,上柱,以初始流动相平衡。
4.如权利要求1所述的提取分离方法,其特征在于,所述步骤2中所用乙酸乙酯洗脱程序为等度洗脱。
5.如权利要求1所述的提取分离方法,其特征在于,所述步骤4中的硅胶层析分离用乙酸乙酯进行等度洗脱。
6.如权利要求1所述的提取分离方法,其特征在于,所述步骤5中所采用甲醇等度洗脱。
7.如权利要求1所述的提取分离方法,其特征在于,步骤6中所述甲醇和水的体积比为85∶15。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110642216.8A CN114369022B (zh) | 2021-06-09 | 2021-06-09 | 马齿苋中一种有机酸类化合物及其提取分离方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110642216.8A CN114369022B (zh) | 2021-06-09 | 2021-06-09 | 马齿苋中一种有机酸类化合物及其提取分离方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114369022A CN114369022A (zh) | 2022-04-19 |
CN114369022B true CN114369022B (zh) | 2022-11-11 |
Family
ID=81138142
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110642216.8A Active CN114369022B (zh) | 2021-06-09 | 2021-06-09 | 马齿苋中一种有机酸类化合物及其提取分离方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114369022B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116283510B (zh) * | 2023-04-12 | 2024-03-01 | 辽宁中医药大学 | 马齿苋中一种新型苯酚类化合物及其提取分离方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101643403A (zh) * | 2009-04-10 | 2010-02-10 | 陈海燕 | 一种从马齿苋中提取亚麻酸的方法 |
CN101888839A (zh) * | 2007-10-12 | 2010-11-17 | 雷索维克斯药品公司 | 治疗眼睛病症的脂氧化物类化合物 |
CN110272369A (zh) * | 2019-07-16 | 2019-09-24 | 辽宁中医药大学 | 马齿苋中一种吡咯二羧酸类化合物及其提取分离方法与用途 |
CN112479887A (zh) * | 2020-11-26 | 2021-03-12 | 辽宁中医药大学 | 马齿苋中一种酯类化合物及其提取分离方法和应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008070129A2 (en) * | 2006-12-05 | 2008-06-12 | Resolvyx Pharmaceuticals, Inc. | Compositions and methods for the treatment of inflammatory disease |
WO2010039529A2 (en) * | 2008-09-23 | 2010-04-08 | Resolvyx Pharmaceuticals, Inc. | Compositions and methods for the treament of inflammatory disease |
-
2021
- 2021-06-09 CN CN202110642216.8A patent/CN114369022B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101888839A (zh) * | 2007-10-12 | 2010-11-17 | 雷索维克斯药品公司 | 治疗眼睛病症的脂氧化物类化合物 |
CN101643403A (zh) * | 2009-04-10 | 2010-02-10 | 陈海燕 | 一种从马齿苋中提取亚麻酸的方法 |
CN110272369A (zh) * | 2019-07-16 | 2019-09-24 | 辽宁中医药大学 | 马齿苋中一种吡咯二羧酸类化合物及其提取分离方法与用途 |
CN112479887A (zh) * | 2020-11-26 | 2021-03-12 | 辽宁中医药大学 | 马齿苋中一种酯类化合物及其提取分离方法和应用 |
Non-Patent Citations (1)
Title |
---|
马齿苋多不饱和脂肪酸的研究进展;李冠文 等;《食品安全质量检测学报》;20200731;第11卷(第14期);第4549-4555页 * |
Also Published As
Publication number | Publication date |
---|---|
CN114369022A (zh) | 2022-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110272369B (zh) | 马齿苋中一种吡咯二羧酸类化合物及其提取分离方法与用途 | |
CN108084060B (zh) | 马齿苋中生物碱oleraurea及其提取分离方法 | |
CN115716790B (zh) | 马齿苋中一种酰胺酯类生物碱的提取分离方法及其应用 | |
CN112300000B (zh) | 马齿苋中一种具有抗肿瘤和抗胆碱酯酶活性的酯类化合物及其提取分离方法和应用 | |
CN111303154B (zh) | 马齿苋中一种具有抗炎活性生物碱及其提取分离方法与用途 | |
CN113321618B (zh) | 马齿苋中三种生物碱类化合物及其提取分离方法 | |
CN113264886B (zh) | 马齿苋中一种哒嗪类化合物的提取分离方法及其应用 | |
CN114369022B (zh) | 马齿苋中一种有机酸类化合物及其提取分离方法 | |
CN114213473A (zh) | 马齿苋中三种生物碱类化合物及其提取分离方法 | |
CN115724812B (zh) | 马齿苋中一种呋喃酯类生物碱的提取分离方法及其应用 | |
CN115521245B (zh) | 马齿苋中一种生物碱类化合物及其提取分离方法与应用 | |
CN114989084B (zh) | 马齿苋中一种四氢异喹啉类生物碱的提取分离方法及其应用 | |
CN113968862B (zh) | 马齿苋中两种新生物碱及其提取分离方法 | |
CN113968785B (zh) | 马齿苋中一种含氧苯甲酸及其提取分离方法与应用 | |
CN114369076B (zh) | 马齿苋中两种茚类化合物及其提取分离方法 | |
CN113264829B (zh) | 马齿苋中四种木脂素及其提取分离方法 | |
CN116621785B (zh) | 马齿苋中一种新生物碱类化合物及其提取分离方法 | |
CN116284005B (zh) | 马齿苋中一种新生物碱及其提取分离方法 | |
CN113912657B (zh) | 马齿苋中三种吲哚类生物碱及其提取分离方法与用途 | |
CN116283510B (zh) | 马齿苋中一种新型苯酚类化合物及其提取分离方法 | |
CN113968817B (zh) | 马齿苋中两种四氢异喹啉的提取分离方法及其应用 | |
CN116730891B (zh) | 马齿苋中两种新生物碱类化合物及其提取分离方法 | |
CN113307817B (zh) | 马齿苋中一种吡咯类生物碱化合物及其提取分离方法 | |
CN115385884B (zh) | 马齿苋中一种新色酮醇类的提取分离方法及其应用 | |
CN116606286B (zh) | 马齿苋中呋喃类生物碱及其提取分离方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |